Article Text

Download PDFPDF

THU0472 FAST3 (fibromyalgia assessment screening test): a composite index based on mdhaq provides clues to the presence of secondary fibromyalgia in patients with a primary diagnosis of rheumatoid arthritis at higher levels than identified in the medical record: a cross sectional study from routine care
  1. I Castrejon1,
  2. K Gibson2,
  3. JA Block1,
  4. T Pincus1
  1. 1Rheumatology, Rush University Medical Center, Chicago, United States
  2. 2Rheumatology, Liverpool Hospital, Sydney, Australia


Background Secondary fibromyalgia (FM) is reported in 17% of RA patients1, but may be under-recognized in patients with classical RA findings. A FAST3 (fibromyalgia assessment screening test) index based on 3 MDHAQ (Multidimensional Health Assessment Questionnaire) scores gives similar results to ACR fibromyalgia criteria based on a widespread pain questionnaire,2 to assist in recognizing patients with secondary FM3.

Objectives To study patients with a primary diagnosis of RA seen in routine care for the proportion identified as having secondary FM according to a physician diagnosis in the medical record versus a FAST3 Index of MDHAQ scores.

Methods All patients complete an MDHAQ/RAPID3 at all visits in the waiting area in routine care. The MDHAQ includes 0–10 scores for physical function, pain, and patient global estimate, compiled into RAPID3, as well as a 0–48 RADAI self-report score of painful joints, and 0–60 symptom checklist. FAST3 has been developed previously as the 0–3 sum of 1 point each for 3 MDHAQ scores: pain VAS ≥6, RADAI ≥16, and symptom checklist ≥16.3 FAST scores of ≥2/3 had >80% agreement with ACR FM criteria based on a widespread pain questionnaire2 to identify secondary FM.3 A random visit for each patient with a primary diagnosis of RA with complete data was studied. The number with a diagnosis of secondary FM in the medical record was compared to the number with FAST3 scores of 0, 1, 2, 3, and with each of the 3 FAST3 components. Receiver-operating characteristic (ROC) curves were generated to estimate sensitivity and specificity for each cut-point of the FAST3 score, using a diagnosis of secondary FM by the physician as the external criterion.

Results 287 patients with RA were studied, of whom 10 (3.3%) had a diagnosis of secondary FM by the physician in the medical record and 61 (22%) had FAST3 scores of 2 or 3 (Table), including 6 of 10 identified as having FM in the medical record. Overall, FAST3 was 0 in 161 RA patients (56%), 1 in 59 (20.6%), 2 in 46 (16%), and 3 in 21 (7.3%) (Table). Overall, 55 additional RA patients were identified by FAST3 versus the medical record as having possible secondary FM. The ROC area was 0.73 (95% CI, 0.57–0.89) (data not shown).

Table 1.

FAST3 (fibromyalgia assessment screening tool) Index and 3 individual components according to diagnosis of fibromyalgia by rheumatologist in medical record

Conclusions The same MDHAQ used to score RAPID3 may also provide a FAST3 score as a screening tool for secondary FM in RA (and other) patients (including primary FM). Secondary FM may be under-diagnosed by clinicians in routine care. Further validation of FAST3 in other settings is needed.


  1. Wolfe F, et al. J Rheum 2011;31:695–700.

  2. Wolfe et al, J Rheumatol 2011;38:1113–22.

  3. Gibson K, et al. Arthritis Rheumatol. 2016; 68 (suppl. 10).


Disclosure of Interest I. Castrejon: None declared, K. Gibson: None declared, J. Block: None declared, T. Pincus Shareholder of: Health Report Services, Inc

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.